Tuberculosis after conversion from azathioprine to mycophenolate mofetil in a long-term renal transplant recipient

Transplantation Proceedings

Volumn 37, Issue 10, 2005, Pages 4241-4243

  Mercadal, L ^a   Foltz, V ^a   Isnard Bagnis, C ^a   Ourahma, S ^a   Deray, G ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; ISONIAZID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; ARTICLE; CASE REPORT; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; AZATHIOPRINE; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 29544434525     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2005.11.010     Document Type: Article

References (23)

1. N. Singh, D.L. Paterson Mycobacterium tuberculosis infection in solid-organ transplant recipients. Impact and implication for management Clin Infect Dis 27 1998 1266
2. J. Waiser, R. Schötschel, K. Budde Reactivation of tuberculosis after conversion from azathioprine to mycophenolate mofetil 16 years after renal transplantation Am J Kidney Dis 35 2000 E12
3. H. Skhiri, Y. Guedri, Y. Souani Primary tuberculosis 1 year after conversion from azathioprine to mycophenolate in recipient kidney transplantation case report Transplant Proc 35 2003 2678
4. C.L. The, K.O. Kong, A.P. Chong Mycobacterium haemophilium infection in an SLE patient on mycophenolate mofetil Lupus 11 2002 249
5. The Tricontinental Mycophenolate Cooperative Study Group A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation Transplantation 61 1996 1029
6. P. Halloran, T. Mathew, S. Tomlanovich Mycophenolate mofetil in renal allograft recipients a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection Transplantation 63 1997 39
7. European Mycophenolate Mofetil Cooperative Study Group Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection Lancet 345 1995 1321
8. A.O. Ojo, H.U. Meier-Kriesche, J.A. Hanson Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection Transplantation 69 2000 2405
9. G.A. Knoll, I. MacDonald, A. Khan Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation J Am Soc Nephrol 14 2003 2381
10. J.P. Squifflet, L. Backman, K. Claesson Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients Transplantation 72 2001 63
11. D.W. Johnson, D.L. Nicol, D.M. Purdie Is mycophenolate mofetil less safe than azathioprine in elderly renal transplant recipients? Transplantation 73 2002 1158
12. K.C. Abbott, I.O. Hypolite, R. Viola Hospitalizations for cytomegalovirus disease after renal transplantation in the United States Ann Epidemiol 12 2002 402
13. E.F. de Maar, E.A. Verschuuren, J.J. Homan vd heide Effects of changing immunosuppressive regimen on the incidence, duration and viral load of cytomegalovirus infection in renal transplantation a single center report Transplant Infect Dis 4 2002 17
14. C.G. ter Meulen, J.F. Wetzels, L.B. Hillbrands The influence of mycophenolate mofetil on the incidence and the severity of primary cytomegalovirus infections and disease after renal transplantation Nephrol Dial Transplant 15 2000 711
15. J.M. Sarmiento, D.H. Dockrell, T.R. Schwab Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients Clin Transplant 14 2000 136
16. US Renal Transplant Mycophenolate Mofetil Study Group Mycophenolate mofetil in cadaveric renal transplantation Am J Kidney Dis 34 1999 296
17. M. Baudard, A. Vincent, P. Moreau Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications a series of 21 BM or PBSC transplanted patients Bone Marrow Transplant 30 2002 287
18. L. Hambach, M. Stadler, E. Damman Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation Bone Marrow Transplant 29 2002 903
19. W.S. Rothwell, J.M. Gloor, B.Z. Morgenstem Disseminated varicella infection in pediatric renal transplant recipients treated with mycophenolate mofetil Transplantation 68 1999 151
20. P. Hutchinson, S.J. Chadban, R.C. Atkins Laboratory assessment of immune function in renal transplant patients Nephrol Dial Transplant 18 2003 983
21. R. Corales, J. Chua, S. Mawhorter Significant post-transplant hypogammaglobulinemia in six heart transplant recipients an emerging clinical phenomenon? Transplant Infect Dis 2 2000 133
22. R. Ganschow, M. Lyons, M.J. Kemper B-cell dysfunction and depletion using mycophenolate mofetil in a pediatric combined liver and kidney graft recipient Pediatr Transplant 5 2001 60
23. S.C. Zmonarski, M. Boratynska, K. Madziarska Mycophenolate mofetil severely depresses antibody response CMV infection in early posttransplant period Transplant Proc 35 2003 2205